This randomized, single-dose, three-way, crossover study is conducted to compare the relative bioavailability of three formulations of sertraline hydrochloride tablets under fasting conditions in 24 healthy adults male volunteers. In each study period, a single 100 mg dose is administered to the subjects following an overnight fast of at least 10 hours. The test formulations are sertraline hydrochloride 50 and 100 mg tablets manufactured by Sobhandarou and the reference formulation is ZOLOFT® (sertraline hydrochloride) 100 mg tablet manufactured by Pfizer. The subjects will receive the test products and the reference product in three periods; the order of administration will be according to the dosing randomization schedule. There will be a 7-day interval between treatments. Venous blood (3 ml) for the determination of sertraline in plasma is sampled before dosing and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours after dosing (a total of 14 samples per profile). Criteria for the evaluation include the time course of the plasma concentrations of sertraline over the 72 h after the administration of the products as summarized by the area under the curve from time zero to infinity (AUC0-inf), the maximum plasma concentration (Cmax), time to reach Cmax (Tmax) and plasma half-life (t1/2). Statistical analysis is performed to evaluate the relative bioavailability of the test formulations to that of the reference product.